At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BIB ProShares Ultra Nasdaq Biotechnology
Market Closed 07-10 16:00:00 EDT
102.92
-5.57
-5.13%
盘后102.71
-0.21-0.21%
18:51 EDT
High109.78Low101.50Vol29.08K
Open109.78D1 Closing108.49Amplitude7.63%
Mkt Cap86.46MTradable Cap86.46MTotal Shares840.00K
T/O3.00MT/O Rate3.46%Tradable Shares840.00K
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Crinetics Pharmaceuticals Announces Merger Agreement With Vertex
TIPRANKS  ·  07-11 04:34
Crinetics Pharmaceuticals Announces Merger Agreement With Vertex
Moderna Inc. Stock Falls 10.8%, Underperforms Peers
Dow Jones  ·  07-11 04:33
Moderna Inc. Stock Falls 10.8%, Underperforms Peers
Gilead Sciences Down over 4%, on Pace for Largest Percent Decrease Since July 2025
Dow Jones  ·  07-11 01:15
Gilead Sciences Down over 4%, on Pace for Largest Percent Decrease Since July 2025
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement
TradingKey  ·  07-11 00:15
Gilead Sciences Inc Stock (GILD) Moved Down by 3.26% on Jul 10: Facts Behind the Movement
Biopharma Dealmaking on Way to Record Year, Says HSBC
Reuters  ·  07-10 18:33
Biopharma Dealmaking on Way to Record Year, Says HSBC
Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors
Dow Jones  ·  07-10 16:31
Sino Biopharmaceutical Stock Advances 3.8% in Hong Kong, Outperforms Competitors
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Dow Jones  ·  07-10 04:33
Amgen Inc. Stock Outperforms Competitors Despite Losses on the Day
Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors
Dow Jones  ·  07-09
Sino Biopharmaceutical Stock Rises 3.7% in Hong Kong, Outperforms Competitors
Moderna Inc. Stock Slips 7.5%, Underperforms Peers
Dow Jones  ·  07-09
Moderna Inc. Stock Slips 7.5%, Underperforms Peers
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled
TradingKey  ·  07-09
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled
Amgen Targets Carbon Neutrality by 2027 for Owned, Operated Facilities and Operations
Reuters  ·  07-09
Amgen Targets Carbon Neutrality by 2027 for Owned, Operated Facilities and Operations
Amgen is Maintained at Equal-weight by Morgan Stanley
Dow Jones  ·  07-09
Amgen is Maintained at Equal-weight by Morgan Stanley
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
MT Newswires Live  ·  07-08
Biopharma Sector Seen Shifting to Fundamentals From Macro in H2, Morgan Stanley Says
Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)
TIPRANKS  ·  07-08
Analysts Conflicted on These Healthcare Names: Certara (CERT), Nurix Therapeutics (NRIX) and Vertex Pharmaceuticals (VRTX)
Morgan Stanley's Analysis of Vertex's Major Acquisition of Crinetics: Enhancing Endocrine Portfolio and Unlocking Growth Potential
Stock News  ·  07-08
Morgan Stanley's Analysis of Vertex's Major Acquisition of Crinetics: Enhancing Endocrine Portfolio and Unlocking Growth Potential
Gilead price target lowered to $166 from $168 at Morgan Stanley
TIPRANKS  ·  07-08
Gilead price target lowered to $166 from $168 at Morgan Stanley
Gilead Sciences (GILD) Could Be 53% Below Fair Value After Trodelvy Approval
Simply Wall St.  ·  07-08
Gilead Sciences (GILD) Could Be 53% Below Fair Value After Trodelvy Approval
Crinetics downgraded to In Line from Outperform at Evercore ISI
TIPRANKS  ·  07-08
Crinetics downgraded to In Line from Outperform at Evercore ISI
Vertex (VERX) Could Be 28% Undervalued As TD Cowen Backs Its Profit Plan
Simply Wall St.  ·  07-08
Vertex (VERX) Could Be 28% Undervalued As TD Cowen Backs Its Profit Plan
Press Release: Vertex to Announce Second Quarter 2026 Financial Results on August 3rd
Dow Jones  ·  07-08
Press Release: Vertex to Announce Second Quarter 2026 Financial Results on August 3rd

Introduction

Company Name.
ProShares Ultra Nasdaq Biotechnology
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.
Issue price:
--